Mirena (Levonorgestrel)

Levonorgestrel, the active ingredient in Mirena, is a progestin presented as a 52 mg intrauterine system for intrauterine use. It provides contraception and reduces heavy menstrual bleeding in women of reproductive age.

GNH USA supplies Mirena as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levonorgestrel delivered via Mirena acts on the hormonal regulation of the reproductive system.

- Contraception: provides highly effective long‑term birth control for up to five years. - Heavy menstrual bleeding: reduces menstrual blood loss and improves anemia. - Benign endometrial hyperplasia: helps manage non‑cancerous overgrowth of the endometrium.

Common side effects are generally mild and related to the local hormonal action of the device.

Common Side Effects: - Altered bleeding patterns: spotting, irregular bleeding, or amenorrhea. - Pelvic or cramping pain during and after insertion. - Breast tenderness or enlargement. - Mood changes or mild depression. - Headache. - Nausea.

Serious or Rare Side Effects: - Uterine perforation during insertion. - Device expulsion or displacement. - Pelvic inflammatory infection. - Ovarian cyst formation. - Allergic reaction to device components. - Ectopic pregnancy if contraception fails.

Before insertion, clinicians should evaluate patient history and ensure appropriate conditions for safe use. - Pregnancy status: confirm the patient is not pregnant before insertion. - Uterine abnormalities: assess for fibroids, congenital anomalies, or scarring. - Active pelvic infection: defer insertion until infection resolves. - Bleeding changes: counsel patients about possible irregular bleeding or amenorrhea. - Signs of perforation: monitor for severe abdominal pain or abnormal bleeding. - Store at room temperature: keep in the original pack, protect from moisture.

Levonorgestrel released from Mirena may have its efficacy altered by concomitant medications that affect steroid metabolism.

Major Interactions (Avoid): - Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin) that lower levonorgestrel levels. - Rifampin or other strong CYP3A inducers that may reduce contraceptive effectiveness. - St. John’s wort, a herbal CYP3A inducer, potentially decreasing hormone exposure.

Moderate Interactions (Monitor Closely): - Antiretroviral agents (e.g., efavirenz) that may modestly reduce hormone levels. - Azole antifungals (e.g., ketoconazole) that could increase levonorgestrel concentrations. - Combined hormonal contraceptives used concurrently; monitor for additive hormonal effects.